Audience · Practical Guide
Fact-checked by Dr. Adam Kennah, MD on . See our fact-checking policy.
Men over 40 face a specific cluster of metabolic problems: visceral adiposity, declining testosterone, rising cardiovascular risk, increasing prevalence of obstructive sleep apnea, and metabolic syndrome. GLP-1 therapy addresses several of these simultaneously, but the considerations for a 45-year-old man are not identical to those for a 30-year-old woman.
By age 40, the average American man has visceral fat in the metabolically significant range, fasting insulin trending upward, declining total testosterone, and rising blood pressure. This is the population in which obstructive sleep apnea quietly becomes prevalent, often undiagnosed, and in which the first cardiovascular event begins to appear within the next decade.
GLP-1 therapy intervenes at several points in this cascade. Visceral fat — the dangerous fat — comes off preferentially. Insulin sensitivity improves. Blood pressure typically falls 3–5 mmHg. Lipids improve. And, in patients with established CV disease, semaglutide 2.4 mg has been shown to reduce MACE by 20% (SELECT trial).
Approximately 30–40% of men with obesity have low total testosterone, most commonly secondary hypogonadism driven by adiposity. Weight loss reliably restores testosterone toward normal. In published cohorts, every 1 kg of weight lost corresponds to roughly a 2.1 ng/dL rise in total testosterone — meaningful at the 15–25 kg loss range typical with GLP-1 therapy.
The implication: in a man with obesity and low testosterone, GLP-1 therapy is often a more biologically reasonable first step than starting exogenous testosterone, which suppresses endogenous production and complicates fertility.
All weight loss methods lose some lean mass alongside fat mass. The fraction lost as lean mass tends to be 20–30% of total weight loss. For men over 40, this matters more than for younger patients because age-related sarcopenia is already in motion.
Two interventions reliably preserve lean mass during GLP-1-mediated weight loss:
This is not optional. A man losing 20 kg over 12 months without resistance training and protein discipline will lose 4–6 kg of lean mass — a meaningful hit at this life stage.
An estimated 30% of men with obesity have undiagnosed obstructive sleep apnea. Symptoms (loud snoring, witnessed apneas, daytime sleepiness, morning headaches) should prompt a sleep study before or shortly after starting GLP-1 therapy. Tirzepatide now has an FDA OSA indication if BMI is high enough (see our sleep apnea page).
Will it lower my testosterone? Indirectly through weight loss it raises endogenous testosterone in men with obesity-related low T. It does not directly suppress the HPG axis.
Will it make me lose muscle? Some lean mass loss is inevitable. Resistance training and adequate protein limit it to a clinically insignificant amount.
Will it affect libido or erectile function? Most men report improvement, consistent with the metabolic improvements driving better endothelial function. A minority report nausea-related libido decrease during titration.
Can I drink alcohol? Tolerance often decreases. Many men report reduced desire to drink — an interesting and reproducible class effect of GLP-1s.
For men 40+ with BMI ≥27 and CV risk factors, the question is less which provider and more which medication has the indication that matches your risk profile. See our NexLife review for the full breakdown.